Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adaptimmune Ther ADR (NQ: ADAP )

1.190 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 852,996
Open 1.220
Bid (Size) 1.210 (1)
Ask (Size) 1.230 (22)
Prev. Close 1.190
Today's Range 1.170 - 1.240
52wk Range 0.4200 - 2.050
Shares Outstanding 1,480,950,456
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining... 
Via Newsfile
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga

Performance

YTD
+59.52%
+59.52%
1 Month
-13.77%
-13.77%
3 Month
+14.42%
+14.42%
6 Month
+112.50%
+112.50%
1 Year
-14.39%
-14.39%

More News

Read More
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
Via Newsfile
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Via Newsfile
Adaptimmune Therapeutics Earnings Preview
Via Benzinga
Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday
Via Benzinga
Topics Stocks
Exposures US Equities
ADAP Stock Earnings: Adaptimmune Therapeutics Misses EPS, Misses Revenue for Q4 2023
Via InvestorPlace
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
Via Newsfile
Topics Economy
Exposures Product Safety Supply Chain
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
Via Newsfile
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
Via Newsfile
Earnings Scheduled For March 6, 2024
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
Via Newsfile
Exposures Product Safety
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
Via Newsfile
Exposures Product Safety
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
Via Newsfile
Exposures Product Safety
Adaptimmune Receives Transfer of IND for Lete-cel Program
Via Newsfile
Adaptimmune Reports Third Quarter Financial Results and Business Update
Via Newsfile
Adaptimmune Selects ADP-600 as Clinical Candidate for Best-in Class PRAME Strategy
Via Newsfile
Adaptimmune Reports Better Outcomes for People with Synovial Sarcoma who Received Afami-cel Compared to Historical Control
Via Newsfile
Adaptimmune Reports Positive Data with Lete-cel[1] from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
Via Newsfile
Adaptimmune to Report Q3 2023 Financial and Business Updates on Wednesday, November 8, 2023
Via Newsfile
Next-Generation TCR T-cell Therapy (ADP-A2M4CD8) Demonstrates Strong Efficacy in a Broad Range of Solid Tumors; Adaptimmune Presents Data Update from its SURPASS trial at ESMO
Via Newsfile
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.